Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

被引：0
|
作者：
Yang, James Chih-Hsin
Chen, Yuh-Min
Batra, Ullas
Do, Kien
Sitthideatphaiboon, Piyada
Danchaivijitr, Pongwut
Lee, Kang-Yun
Chindaprasirt, Jarin
Yang, Cheng-Ta
Chang, Gee-Chen
Charoentum, Chaiyut
Ungtrakul, Teerapat
Moran, Juan Ignacio Hernandez
Hartmaier, Ryan
Haskins, Matthew
Xu, Wanning
Riess, Jonathan W.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT251
引用
收藏
页数：3
相关论文
共 49 条
  • [41] Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
    Wu, Yi-Long
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jin-Ji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen Viet
    Chia, Puey Ling
    de Marinis, Filippo
    Raskin, Jo
    Zhou, Qinghua
    Finocchiaro, Giovanna
    Le, Anh Tuan
    Wang, Jialei
    Dooms, Christophe
    Kato, Terufumi
    Nadal, Ernest
    Hin, How Soon
    Smit, Egbert F.
    Wermke, Martin
    Tan, Daniel
    Morise, Masahiro
    O'Brate, Aurora
    Adrian, Svenja
    Pfeiffer, Boris M.
    Stroh, Christopher
    Juraeva, Dilafruz
    Strotmann, Rainer
    Goteti, Kosalaram
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Le, Xiuning
    Kim, Tae Min
    LANCET ONCOLOGY, 2024, 25 (08): : 989 - 1002
  • [42] The preliminary safety result of a phase II study of osimertinib in combination with platinum plus pemetrexed in patients with previously untreated EGFR-mutated advanced NSCLC (NEJ032C/LOGIK1801: OPAL)
    Morita, R.
    Asahina, H.
    Tanaka, K.
    Saito, R.
    Sugawara, S.
    Ko, R.
    Azuma, K.
    Morita, S.
    Saijo, Y.
    Maemondo, M.
    Seike, M.
    Isamu, O.
    Sugio, K.
    Kobayashi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1390 - S1390
  • [43] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
    Mok, T. S. K.
    Nakagawa, K.
    Park, K.
    Ohe, Y.
    Girard, N.
    Kim, H. R.
    Wu, Y-L.
    Gainor, J.
    Lee, S-H.
    Chiu, C-H.
    Sang-We, K.
    Cheng-Ta, Y.
    Liang, W.
    Wu, L.
    Lin, M-C.
    Samol, J.
    Zhang, X.
    Sylvester, J.
    Li, S.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1561 - S1562
  • [44] Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates
    Horinouchi, H.
    Cho, B. C.
    Camidge, D. R.
    Goto, K.
    Tomasini, P.
    Li, Y.
    Vasilopoulos, A.
    Brunsdon, P.
    Hoffman, D.
    Shi, W.
    Blot, V.
    Goldman, J. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1670 - S1670
  • [45] RELAY study of erlotinib (ERL) plus ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).
    Nishio, Kazuto
    Sakai, Kazuko
    Seto, Takashi
    Nishio, Makoto
    Garon, Edward B.
    Reck, Martin
    Goto, Koichi
    Kato, Terufumi
    Nakanishi, Yoichi
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Kiura, Katsuyuki
    Ohe, Yuichiro
    Tamura, Tomohide
    Visseren-Grul, Carla M.
    Hozak, Rebecca R.
    Wijayawardana, Sameera R.
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Nonsmall Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial (Previously presented at ESMO Congress 2023, FPN:LBA14, Byoung Chul Cho et al. - Reused with permission.)
    Schuler, Martin
    Cho, Byoung Chul
    Felip, Enriqueta
    Spira, Alexander
    Girard, Niolas
    Lee, Jong-Seok
    Lee, Se-Hoon
    Ostapenko, Yuriy
    Danchaivijitr, Pongwut
    Liu, Baogang
    Alip, Adlinda
    Korbenfeld, Ernesto
    Mourao, Josiane
    Sun, Tao
    Martinez, Melissa
    Bauml, Joshua
    Shreeve, Martin
    Sethi, Seema
    Knoblauch, Roland
    Hayashi, Hidetoshi
    Lu, Shun
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 260 - 261
  • [48] Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm plus ) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial
    Schuler, M.
    Tan, E-H.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T. S. K.
    Hirsh, V.
    Yang, J. C-H.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S-W.
    Laskin, J.
    Kim, D-W.
    Arvis, C. Dubos
    Kolbeck, K.
    Massey, D.
    Fan, J.
    Paz-Ares, L.
    Park, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] GEOMETRY duo-1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum plus pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy.
    Smit, Egbert F.
    Kopp, Hans-Georg
    Kim, Dong-Wan
    Tortora, Giampaolo
    Spira, Alexander I.
    Berruti, Alfredo
    Lee, Dae Ho
    Reguart, Noemi
    Rybkin, Igor I.
    Akimov, Mikhail
    Schumacher, Karl Maria
    Upalawanna, Allison
    Xu, Cindy
    Squires, Matthew
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345